Clinical trials / Anxiety
Recruiting psychedelic and ketamine trials for anxiety
13 trials registered on ClinicalTrials.gov were recruiting on 26 Oct 2026, 9 of them at sites in the United States (6 states). By substance: Ketamine / esketamine 7, Psilocybin 5, LSD 1.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Trials with US sites
ObservationalKetamine / esketamineNCT06070766
RIVER At Home Ketamine Protocols
- Conditions:
- Chronic Condition; Chronic Pain; Chronic Disease; Major Depressive Disorder; Post Traumatic Stress Disorder; Anxiety Disorders
- Sponsor:
- RIVER Foundation
- Who:
- ages 18 Years and over, 50000 participants planned
- RIVER Foundation, Bigfork, Montana
- RIVER Telehealth, Helena, Montana
Phase 4Ketamine / esketamineNCT05934669
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
- Conditions:
- Laceration of Skin; Anxiety; Discharge Time
- Sponsor:
- University of Oklahoma
- Who:
- ages 1 Year to 5 Years, 90 participants planned, accepts healthy volunteers
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
ObservationalKetamine / esketamineNCT06038409
Ketamine Treatment Plans for Chronic Conditions
- Conditions:
- Chronic Pain; Depressive Disorder; Anxiety Disorders; Chronic Disease
- Sponsor:
- RIVER Foundation
- Who:
- ages 18 Years and over, 500 participants planned
- RIVER Telehealth, Helena, Montana
Phase 2PsilocybinNCT06200155
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
- Conditions:
- Depression, Anxiety; Psilocybin-Assisted Psychotherapy; Advanced Cancer
- Sponsor:
- M.D. Anderson Cancer Center
- Who:
- ages 25 Years and over, 48 participants planned
- MD Anderson Cancer Center, Houston, Texas
Phase 1PsilocybinNCT06442423
Open-Label Psilocybin Study in Transdiagnostic Population
- Conditions:
- Transdiagnostic; Depression - Major Depressive Disorder; Anxiety; PTSD Symptoms; PTSD; Substance Use; Substance Use Disorder (SUD); OCD
- Sponsor:
- Yale University
- Who:
- ages 18 Years and over, 50 participants planned, accepts healthy volunteers
- Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut
Phase 3Ketamine / esketamineNCT06752759
Nebulized Ketamine for the Treatment of Major Depressive Disorder
- Conditions:
- Severe Depression; Moderate Depression; Ketamine; Midazolam; Peripheral Nervous System Agents; Central Nervous System Agents; Neurotransmitter Agents; Physiologic Effects of Drugs; Sensory System Agents; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Depressive Symptom; Hypnotics and Sedatives; Anti-anxiety Agents; Tranquilizing Agents; Psychotropic Drugs; Anesthetics Agent
- Sponsor:
- Theresa Jacob, PhD, MPH
- Who:
- ages 18 Years to 88 Years, 40 participants planned
- Maimonides Medical Center, Brooklyn, New York
Phase 2PsilocybinNCT06801041
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
- Conditions:
- Depression; Anxiety; Cancer
- Sponsor:
- M.D. Anderson Cancer Center
- Who:
- ages 18 Years and over, 20 participants planned
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Phase 2PsilocybinNCT06899165
Psilocybin-Assisted Therapy for Intergenerational Trauma
- Conditions:
- Psychological Stress; Depression; Anxiety
- Sponsor:
- Rachel Yehuda
- Who:
- ages 18 Years and over, 100 participants planned
- The Parsons Research Center for Psychedelic Healing, New York, New York
ObservationalKetamine / esketamineNCT06997549
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
- Conditions:
- Depression; OCD; Anxiety Depression
- Sponsor:
- Neuronetics
- Who:
- ages 5 Years to 100 Years, 12000 participants planned
- Neuronetics, Malvern, Pennsylvania
Trials outside the United States
Phase 2LSDNCT05883540
Lysergic Acid Diethylamide (LSD) in Palliative Care (LPC)
- Conditions:
- Palliative Care; Pain; Anxiety; Depression; Demoralization; Psychological Distress; Quality of Life; Caregiver Burden; Fear of Death; Existential Distress
- Sponsor:
- University Hospital, Basel, Switzerland
- Who:
- ages 22 Years and over, 60 participants planned
- Where:
- Switzerland
Phase 4Ketamine / esketamineNCT06853431
Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia
- Conditions:
- Preoperative Anxiety; Preoperative Sedation; Children; Dexmedetomidine; Esketamine; ED95; ED50; Preoperative Sedation of Children
- Sponsor:
- Second Affiliated Hospital of Wenzhou Medical University
- Who:
- ages 12 Months to 72 Months, 80 participants planned
- Where:
- China
Phase 2PsilocybinNCT06969170
Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
- Conditions:
- Generalized Anxiety Disorder (GAD)
- Sponsor:
- Claudio N Soares
- Who:
- ages 18 Years to 60 Years, 50 participants planned
- Where:
- Canada
ObservationalKetamine / esketamineNCT07146503
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression (ESKPSY)
- Conditions:
- Depression and Quality of Life; Treatment Resistant Depression (TRD); Anhedonia; Apathy; Anxiety; Cognition; Temperament; Psychiatric Comorbidities
- Sponsor:
- Riccardo Guglielmo
- Who:
- ages 18 Years to 74 Years, 100 participants planned
- Where:
- Italy